The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 748K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

23 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Design and synthesis of novel alpha(1)(a) adrenoceptor-selective antagonists. 4. Structure-activity relationship in the dihydropyrimidine series.EBI
Synaptic Pharmaceutical
Design and synthesis of novel alpha(1)(a) adrenoceptor-selective antagonists. 1. Structure-activity relationship in dihydropyrimidinones.EBI
Synaptic Pharmaceutical
Discovery of alpha 1a-adrenergic receptor antagonists based on the L-type Ca2+ channel antagonist niguldipine.EBI
Synaptic Pharmaceutical
Design and synthesis of novel dihydropyridine alpha-1a antagonists.EBI
Synaptic Pharmaceutical
Determination of the relative and absolute stereochemistry of a potent and alpha1A-selective adrenoceptor antagonist.EBI
Synaptic Pharmaceutical
De novo design of a novel oxazolidinone analogue as a potent and selective alpha1A adrenergic receptor antagonist with high oral bioavailability.EBI
Synaptic Pharmaceutical
Synthesis and evaluation of furo[3,4-d]pyrimidinones as selective alpha1a-adrenergic receptor antagonists.EBI
Synaptic Pharmaceutical
Design and synthesis of novel alpha(1)(a) adrenoceptor-selective antagonists. 3. Approaches to eliminate opioid agonist metabolites by using substituted phenylpiperazine side chains.EBI
Synaptic Pharmaceutical
Design and synthesis of novel alpha(1)(a) adrenoceptor-selective antagonists. 2. Approaches to eliminate opioid agonist metabolites via modification of linker and 4-methoxycarbonyl-4-phenylpiperidine moiety.EBI
Synaptic Pharmaceutical
Design and synthesis of novel alpha1a adrenoceptor-selective dihydropyridine antagonists for the treatment of benign prostatic hyperplasia.EBI
Synaptic Pharmaceutical
Design, synthesis and evaluation of substituted triarylnipecotic acid derivatives as GABA uptake inhibitors: identification of a ligand with moderate affinity and selectivity for the cloned human GABA transporter GAT-3.EBI
Synaptic Pharmaceutical
Carboxamide derivatives and use thereofBDB
Purdue Pharma
2,5-disubstituted-pyridyl nicotinic ligands, and methods of use thereofBDB
Georgetown University
5,5-bicyclic oxazole orexin receptor antagonistsBDB
Merck Sharp & Dohme
Metabotropic glutamate receptor negative allosteric modulators (NAMS) and uses thereofBDB
Sanford-Burnham Medical Research Institute
Compounds and methods for kinase modulation, and indications thereforBDB
Plexxikon
Pyrazines as modulators of GPR6BDB
Takeda Pharmaceutical
Substituted 6,5-fused bicyclic heteroaryl compoundsBDB
Epizyme
Identification of a potent new chemotype for the selective inhibition of PDE4.BDB
Nih
Specific Targeting of Highly Conserved Residues in the HIV-1 Reverse Transcriptase Primer Grip Region. 2. Stereoselective Interaction to Overcome the Effects of Drug Resistant Mutations.BDB
Universita Di Siena
Carbonic anhydrase inhibitors: the membrane-associated isoform XV is highly inhibited by inorganic anions.BDB
Universita Degli Studi Di Firenze
Novel inhibitors of fatty acid amide hydrolase.BDB
Bristol-Myers Squibb
Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity.BDB
Pfizer